REG - Eden Research plc - Appointment of Joint Broker

Eden ResearchAnnouncement

10/03/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250310:nRSJ9768Za&default-theme=true

RNS Number : 9768Z  Eden Research plc  09 March 2025

10 March 2025

 

 

Eden Research plc

("Eden" or "the Company")

 

 

Appointment of Joint Broker

 

 

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and
biocontrol technology, is pleased to announce the appointment of Oberon
Capital ("Oberon") as its joint broker with immediate effect.  Oberon will
act alongside Cavendish Capital Markets to enhance brokerage services.

 

Oberon Capital is an independent investment bank with a specialist focus on
London's growth markets, led by a team of veteran brokers with a wealth of
experience across multiple sectors. The firm's appointment is intended to
increase Eden's profile with a new audience of potential investors, build
share register strength and improve share liquidity.

 

Sean Smith, Chief Executive Officer of Eden Research, commented:

 

"We are pleased to appoint Oberon as a joint broker, working closely with
Cavendish. As many AIM investors know all too well, in the current climate
companies such as Eden have struggled with liquidity and attracting the
attention of new investors. We expect Oberon to play an important role in the
Company's future as we seek to increase our exposure to new investors who
value the Company's growing business and its alignment with regulatory
imperatives affecting the agriculture industry across Europe and globally."

 

 

-- ENDS --

 

 

For further information contact:

 

 Eden Research plc
 Sean Smith                                            www.edenresearch.com (http://www.edenresearch.com/)

Alex Abrey

                                                       01285 359 555

 Cavendish Capital Markets Limited

(Nominated advisor and joint broker)
 Giles Balleny / George Lawson (corporate finance)     020 7220 0500

Charlie Combe (corporate broking)

Michael Johnson (sales)

 Oberon Capital (Joint broker)
 Nick Lovering                                         020 3179 5300

 Mike Seabrook

 Adam Pollock

 Hawthorn Advisors (Financial PR)
 Victoria Ainsworth                                    eden@hawthornadvisors.com

 

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative biopesticide
products and natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on
natural plant defence metabolites. To date, they have been primarily used on
high-value fruits and vegetables, improving crop yields and marketability,
with equal or better performance when compared with conventional pesticides.
Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone(®) is a foliar
biofungicide which initially targets a key disease affecting grapes and other
high-value fruit and vegetable crops.  It is a useful tool in crop defence
programmes and is aligned with the requirements of integrated pest management
programmes. It is approved for sale in a number of key countries whilst Eden
and its partners pursue regulatory clearance in new territories thereby
growing Eden's addressable market globally.

 

Novellus®+ is an evolution of Mevalone, allowing improved rates in the
field, high levels of efficacy and a broader list of targets.

 

Cedroz™( )is a bionematicide that targets free living nematodes which are
parasitic worms that affect a wide range of high-value fruit and vegetable
crops globally.  Cedroz is registered for sale on two continents and Eden's
commercial collaborator, Eastman Chemical, is pursuing registration and
commercialisation of this important new product in numerous countries
globally.

 

Eden's seed treatment product, Ecovelex™ was developed to safely tackle
crop destruction caused by birds - a major cause of losses in maize and other
crops. Ecovelex works by creating an unpleasant taste or odour that repels
birds, leaving the seeds safely intact and the birds unaffected and free to
find alternative food sources. The product is based on Eden's plant-derived
chemistry, registered in the EU, U.S. and elsewhere, and formulated using
Eden's Sustaine(®) microencapsulation system.

 

Eden's Sustaine(®)( )encapsulation technology is used to harness the
biocidal efficacy of naturally occurring chemicals produced by plants
(terpenes) and can also be used with both natural and synthetic compounds to
enhance their performance and ease of use. Sustaine microcapsules are
naturally-derived, plastic-free, biodegradable micro-spheres derived from
yeast. It is one of the only viable, proven and immediately registerable
solutions to the microplastics problem in formulations requiring
encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the
symbol EDEN. It was awarded the London Stock Exchange Green Economy
Mark in January 2021, which recognises London-listed companies that derive
over 50% of their total annual revenue from products and services that
contribute to the global green economy. Eden derives 100% of its total annual
revenues from sustainable products and services.

 

For more information about Eden, please visit: www.edenresearch.com
(http://www.edenresearch.com/) . You can also follow Eden's latest
developments via its social media channels: X (Twitter)
(https://twitter.com/edenresearch)  and LinkedIn
(https://www.linkedin.com/company/eden-research-plc/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPFFFVLVFIAIIE